Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation announce the creation of a new resource for IgA nephropathy patients and their loved ones: the IgA nephropathy patient ...

The FDA has granted full approval to iptacopan (Fabhalta) to slow the decline in kidney function in adults with primary ...

Novartis today announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta ® (iptacopan) to slow kidney function decline in adults with primary ...

Iptacopan significantly slowed kidney decline in a phase III trial ...

Medically reviewed by Jamin Brahmbhatt, MD IgA nephropathy (IgAN) is a kidney condition where antibodies (immune system ...

Escalating immunosuppressive therapy is not associated with improved renal or patient survival in rapidly progressive ...

With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, ...

Explore emerging IgA nephropathy therapies—complement and BAFF/APRIL inhibitors, targeted budesonide—and why long‑term safety data still lags. How have the KDIGO thresholds from proteinuria changed ...

Living with the rare condition of IgA nephropathy can feel lonely. Patient advocate Stuart Miller shares his treatment journey and how to stay connected with those who understand. Share on Pinterest ...

No therapies currently exist that can halt the progression of chronic kidney disease in children or restore the ability of kidney cells to filter blood. Recently, researchers at the GOFARR Laboratory ...

The FDA has granted Priority Review to Genentech’s sBLA for obinutuzumab (Gazyva) to treat primary membranous nephropathy, based on phase 3 MAJESTY data.

A recent retrospective study published in the Indian Journal of Nephrology in February 2026 reveals that 60.79% of diabetic ...